Compare · BDX vs MGRM
BDX vs MGRM
Side-by-side comparison of Becton Dickinson and Company (BDX) and Monogram Technologies Inc. (MGRM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and MGRM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX carries a market cap of $42.57B.
- Over the past year, BDX is down 12.2% and MGRM is up 5.3% - MGRM leads by 17.4 points.
- BDX has hit the wire 4 times in the past 4 weeks while MGRM has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 1 for MGRM).
- Company
- Becton Dickinson and Company
- Monogram Technologies Inc.
- Price
- $154.04-0.25%
- $6.00-1.72%
- Market cap
- $42.57B
- -
- 1M return
- +7.01%
- +4.80%
- 1Y return
- -12.17%
- +5.26%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 1
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest MGRM
- SEC Form EFFECT filed by Monogram Technologies Inc.
- SEC Form EFFECT filed by Monogram Technologies Inc.
- SEC Form 15-12G filed by Monogram Technologies Inc.
- SEC Form 4 filed by Director Gray Colleen
- SEC Form 4 filed by Director Gray Colleen
- SEC Form 3 filed by new insider Gray Colleen
- SEC Form S-8 POS filed by Monogram Technologies Inc.
- SEC Form POS AM filed by Monogram Technologies Inc.
- SEC Form POS AM filed by Monogram Technologies Inc.
- SEC Form 4 filed by Director Van Kirk Richard Lee Jr